SGShenglan Gao

Shenglan Gao

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Shenglan Gao has a total of 50 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    SERPINB3 enhances NPM1 sumoylation via inhibiting SENP3’s activity and promotes lung tumorigenesis

    by Xiangyu Meng, Weize Wang, Namratha Sheshadri, Tianyu Zhang, Xinlu Han, Yifu Sun, Man Xiao, Yu Feng, Shan Gao, Jian Chen, et al.

    SERPINB3 or SCCA1, a member of the serine proteinase inhibitor family, is frequently overexpressed in multiple malignancies, including lung adenocarcinoma (LUAD). However, its molecular mechanisms and endogenous substrates in lung cancer remain poorly characterized. Here, we identified SUMO-specific proteinase 3 (SENP3) as a novel direct interaction partner and functional target of SERPINB3 in LUAD. Using proximity-dependent biotin labeling coupled with mass spectrometry, we discovered that SERPINB3 forms a nuclear complex with SENP3 and nucleophosmin (NPM1). This tripartite interaction was validated through endogenous co-immunoprecipitation and bimolecular fluorescence complementation assays. Structural modeling with AlphaFold3 and subsequent mutagenesis studies revealed that SERPINB3 binds specifically to the N-terminal region of SENP3 (amino acids 265-287). Furthermore, our structural and biochemical analyses demonstrate that SENP3 specifically interacts with the C-terminal aromatic domain of NPM1 (amino acids 242-294), while SERPINB3 selectively binds to the pentameric form of NPM1. Mechanistically, SERPINB3 inhibits SENP3’s desumoylation activity, leading to enhanced NPM1 sumoylation in the nucleolus. Functional studies demonstrated that SERPINB3 overexpression (but not the RCL-deleted mutant, SERPINB3△6) promotes LUAD cell proliferation and tumor growth, with NPM1 sumoylation being critical for this oncogenic effect. Clinically, SERPINB3 is highly expressed in human LUAD specimens and co-localizes with SENP3 and NPM1. Our work establishes SENP3 as a bona fide endogenous substrate of SERPINB3 and delineates a novel sumoylation-dependent oncogenic axis in LUAD, offering potential therapeutic targets for this malignancy.

  • Open Access

    TRIM21 knockout alleviates renal fibrosis by promoting autophagic degradation of mature TGF-β1

    by Peng Li, Xinyi Dong, Lijun Xu, Xuetao Hu, Xiangyu Meng, Peng Yang, Xuemei Zhang, Wei-Xing Zong, Shenglan Gao, Shaoyong Zhuang, et al.


  • Open Access

    Glutamine synthetase limits β-catenin–mutated liver cancer growth by maintaining nitrogen homeostasis and suppressing mTORC1

    by Weiwei Dai, Jianliang Shen, Junrong Yan, Alex J. Bott, Sara Maimouni, Heineken Q. Daguplo, Yujue Wang, Khoosheh Khayati, Jessie Yanxiang Guo, Lanjing Zhang, et al.

    Glutamine synthetase (GS) catalyzes de novo synthesis of glutamine that facilitates cancer cell growth. In the liver, GS functions next to the urea cycle to remove ammonia waste. As a dysregulated urea cycle is implicated in cancer development, the impact of GS’s ammonia clearance function has not been explored in cancer. Here, we show that oncogenic activation of β-catenin (encoded by CTNNB1) led to a decreased urea cycle and elevated ammonia waste burden. While β-catenin induced the expression of GS, which is thought to be cancer promoting, surprisingly, genetic ablation of hepatic GS accelerated the onset of liver tumors in several mouse models that involved β-catenin activation. Mechanistically, GS ablation exacerbated hyperammonemia and facilitated the production of glutamate-derived nonessential amino acids, which subsequently stimulated mechanistic target of rapamycin complex 1 (mTORC1). Pharmacological and genetic inhibition of mTORC1 and glutamic transaminases suppressed tumorigenesis facilitated by GS ablation. While patients with hepatocellular carcinoma, especially those with CTNNB1 mutations, have an overall defective urea cycle and increased expression of GS, there exists a subset of patients with low GS expression that is associated with mTORC1 hyperactivation. Therefore, GS-mediated ammonia clearance serves as a tumor-suppressing mechanism in livers that harbor β-catenin activation mutations and a compromised urea cycle.


  • Open Access

    Loss of TRIM21 alleviates cardiotoxicity by suppressing ferroptosis induced by the chemotherapeutic agent doxorubicin

    by Kai Hou, Jianliang Shen, Junrong Yan, Chuannan Zhai, Jingxia Zhang, Ji-An Pan, Ye Zhang, Yaping Jiang, Yongbo Wang, Richard Z. Lin, et al.